CTRI/2021/02/031263尚未招募未知
An Open Label Balanced Randomized Single Dose Four Treatment Four Period Four Sequence Four Way Crossover Study Of Relative Bioavailability Of T1 Curemin Actif Imm capsules 125 Mg Curcuminoids 125 Mg Turmeric Matrix Manufactured By Imm Institut Fuer Mitochondriale Medizin Pfalzburgerstrasse 43/44 10717 Berlin Germany T2 Meriva Thorne Curcumin Phytosome Curcuma Longa Extract Root Phospholipid Complex From Sunflower 500mg Curcumin & Other Curcuminoids 180 Mg Manufactured By Indena s p a Viale Ortles 12 20139 Milano Italy T3 Curcumin Loges capsules Novasol 50.4 Mg Curcuma Extract 35.5 Mg Curcumin Manufactured By DrLoges Co. Gmbh Post Box 1262 Schuetzenstrasse 5 21423 Winsen Luhe Germany T4 Curcumin Intravenous Infusion Burg Apotheke 150 Mg Curcumin Diferuloylmethan Manufactured By Burg Apotheke Koenigstein Frankfurterstrasse 7 16462 Koenigstein Im Taunus Germany In Healthy Adult Human Subjects Under Fed Conditions
Institut fuer mitochondriale Medizin0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Normal, healthy, adult, human subjects of age between 18-45 years with a Body Mass Index (BMI) ranges between 18.50 kg/m2 to 24.99 kg/m2(according to the formula of BMI weight (kg) / [height (m)]2).
- •Subjects who have no evidence of underlying disease during screening and check-in and whose screening is performed within 21 days of check in.
- •Subjects whose screening laboratory values are within normal limits or considered by the physician or principal/clinical investigator to be of no clinical significance.
- •Healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments.
- •Generally healthy as documented by 12-lead electrocardiogram (ECG), X-Ray and clinical laboratory assessments.
- •Non- smokers or ex-smokers. Ex-smokers are defined as someone who has completely stopped smoking for at least the past 03 months.
- •Willing to consume standard breakfast.
- •Willing to comply to all requirements of this study protocol as well as instructed by thestudy personnel
- •Generally healthy as documented by gynecological examination and breast examination (for female subjects â?? period I only).
- •Female subjects within normal limits or clinically non-significant laboratory evaluation results for FSH & LH.
- •Female subjects of childbearing potential;
- •Practicing an acceptable non-hormonal contraceptive method of birth control after consulting with principal investigator; and/or Surgically sterile (bilateral tubal ligation)
排除标准
- •Evidence of allergy or known hypersensitivity to Curcumin or its inactive ingredients.
- •Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse, existing tinnitus and pre-existing gallbladder disease.
- •Any major illness in the last three months or any significant ongoing chronic medical illness.
- •Renal or liver impairment.
- •Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, Musculoskeletal, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •History of alcohol addiction or abuse.
- •Consumption of caffeine and /or Xanthine containing products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) tobacco containing products for at least 48.00 hours prior to dosing and throughout the entire study.
- •Consumption of alcohol and its products, grapefruit and/ or its juice and poppy containing foods within 72.00 hours prior to dosing and throughout the entire study.
- •Subjects should not take any over the counter medicinal products, herbal medications within 07 days prior to study check-in and throughout the study and any prescription medications within 14 days prior to study check-in and throughout the study.
- •An unusual or abnormal diet within 48.00 hours prior to dosing of each period, for whatever reason e.g. because of fasting due to religious reasons.
- •Systolic blood pressure less than 90mrn Hg or more than 140mmHg and diastolic blood pressure less than 60 mmHg or more than 90 mmHg.
- •Subject who had participated in any other study within the 90 days of check-in.
- •History of difficulty in swallowing.
- •History of difficulty in accessibility of veins.
- •Positive results for urine screen of drugs of abuse (Marijuana-THC, amphetamine-AMP, barbiturates-BAR, cocaine-COC, benzodiazepines-BZD and morphine-MOR) in urine prior to check-in of this study period.
- •Positive results for alcohol breath test prior to check-in of each period.
- •Any blood donation / excess blood loss within 90 days of check-in.
- •Ingestion of any hormonal agent at any time within 14 days prior to start of study check-in.
- •Use of hormone replacement therapy for a Period of 06 months prior to dosing.
- •Female subjects demonstrating a positive pregnancy screen.
- •Female subjects whose menstruation cycle coincides with the study periods
- •Female subjects who are currently lactating.
- •Females likely to become pregnant during conducting of the study.
- •Use of hormone replacement therapy for a Period of 06 months prior to dosing.
研究者
相似试验
已完成
Unknown
To study the safety of capsaicin tablets in healthy adult humansCTRI/2023/03/050250Dr Shefali Thanawala
尚未招募
Unknown
To study the comparative bioavailability of Guanfacine suspension in healthy adult volunteersCTRI/2024/07/071015Brillian Pharma Inc
尚未招募
Unknown
To assess the bioavailability of Guanfacine suspension 4 mgCTRI/2024/07/071202Sciecure Pharma Inc
尚未招募
Unknown
Oral pharmacokinetic study of mexiletine hydrochloride 200 mg capsules intended for the cardiovascular disorderCTRI/2024/07/071462DAWA Limited
招募中
Unknown
To evaluate the bioequivalence of Relugolix 120 mg tabletsCTRI/2024/07/070477BDR Pharmaceuticals Internationals Pvt Ltd